SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Summary

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Timeline

Start

2017-04-26

Primary completion

2019-04-19

Completion

2019-04-26

Outcome

Missed primary endpoint

registry Hazard Ratio (HR) 1.129 (95% CI 0.643 to 1.982) NCT03131154 ↗

release “today announced results from the noninfectious anterior uveitis SOLACE Trial. Statistical significance was not achieved for the primary or secondary endpoints” aldeyra.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reproxalap	Other / unclassified	0.5 %	—

Indications